InCarda Therapeutics

In Carda Therapeutics

Biotechnology, Balentine Dr, Newark, , 94560, California, 39899, United States, 11-50 Employees

incardatherapeutics.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 40********

Who is INCARDA THERAPEUTICS

InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product und...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from INCARDA THERAPEUTICS

InCarda Therapeutics Org Chart and Mapping

Employees

Julie Rogers

Contract Clinical Trial Manager

Renata Porto

Vice President, Program and Portfolio Management

Jean Maupas

Director of Data Management

Alice Salvi

Medical Science Liaison

Priscilla Propst

Clinical Research Associate

Natalia Dickinson

Vice President of Quality Assurance

Meisa Propst

Vice President Clinical Operations

Anna Popovici

Vice President, Human Resources

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding InCarda Therapeutics

Answer: InCarda Therapeutics's headquarters are located at Balentine Dr, Newark, , 94560, California, 39899, United States

Answer: InCarda Therapeutics's phone number is 40********

Answer: InCarda Therapeutics's official website is https://incardatherapeutics.com

Answer: InCarda Therapeutics's revenue is $5 Million to $10 Million

Answer: InCarda Therapeutics's SIC: 2836

Answer: InCarda Therapeutics's NAICS: 541714

Answer: InCarda Therapeutics has 11-50 employees

Answer: InCarda Therapeutics is in Biotechnology

Answer: InCarda Therapeutics contact info: Phone number: 40******** Website: https://incardatherapeutics.com

Answer: InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF).

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access